Compare Eli Lilly And Co (LLY) vs Pfizer Inc (PFE) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a bullish technical signal despite near-term resistance. The company maintains solid fundamentals with a P/E of 19.12, net income margin of 11.83%, and consistent quarterly earnings beats. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning for a catalyst-rich 2026.

The outlook is cautiously optimistic, supported by a $28.25 analyst price target and a 38.46% buy rating. Key opportunities include dividend stability and pipeline progress, while risks involve patent cliffs and revenue normalization post-COVID. The stock presents a value proposition for income-focused investors amid ongoing business transformation.